VEEV Stock Recent News
VEEV LATEST HEADLINES
Veeva Systems aims to simplify master data configuration during LIMS implementation and site deployment and enable companies to advance beyond legacy QC systems.
Veeva Systems (VEEV) reachead $223.40 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.
Integration will reduce the burden of master lab data configuration, lowering costs and speeding Veeva LIMS implementation PLEASANTON, Calif. and DEERFIELD, Ill.
Artificial intelligence (AI) was, once again, the hottest investing topic in 2024. It might remain so in 2025, but that doesn't mean there aren't companies in other fields worth investing in.
In the most recent trading session, Veeva Systems (VEEV) closed at $214.75, indicating a +1.43% shift from the previous trading day.
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PLEASANTON, Calif. , Jan. 13, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conference: 27th Annual Needham Growth Conference.
In the latest trading session, Veeva Systems (VEEV) closed at $217.75, marking a +0.21% move from the previous day.
Veeva share price has recently been battling concerns that Salesforce will become a more aggressive competitor and take meaningful market share in Veeva's CRM space. Veeva's financial performance remains strong with high non-GAAP operating margins and free cash flow margins around 40%, positioning it as a GARP investment. The company's strategy includes expanding its Data Cloud and developing horizontal applications, enhancing its comprehensive life sciences cloud offering.
Veeva saw its revenue and non-GAAP operating income grow 13% and 29% YoY in its Q3 FY25 earnings, beating estimates with ongoing momentum in its Development Cloud. The Development Cloud segment, now Veeva's largest revenue contributor, saw 24% YoY growth, driven by deepening adoption across clinical, safety, and quality areas. Despite analyst projections of slower growth, I believe Veeva will meet its $6B revenue target by 2030, supported by its robust product roadmap, genAI innovations, and a favorable macro backdrop.